MEMatthew David Ettleson

Matthew David Ettleson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Matthew David Ettleson has a total of 87 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A Longitudinal, Real-World Study of the Relationship between Levothyroxine Dose and Suboptimal Hypothyroidism Treatment

    by Matthew D. Ettleson, Wen Wan, Neda Laiteerapong, Brian W. Kim, Antonio C. Bianco

    Background: Suboptimal treatment of hypothyroidism with levothyroxine (LT4) is common and associated with adverse cardiovascular outcomes. Patients treated with LT4 doses >100 µg may be at increased risk of under- and overtreatment and therefore may benefit from more frequent thyroid stimulating hormone (TSH) surveillance. Our study aim was to determine the association between LT4 dose and the occurrence of suboptimal treatment within 6 months of a normal TSH value. Methods: A total of 4449 LT4-treated adults were included in a 6-month longitudinal study. All included patients were required to have at least 2 TSH collections over the study period at least 30 days apart. Patients were grouped according to LT4 dose (≤50, 51–100, 101–150, and >150 µg), which served as the primary exposure. Outcomes included the occurrence of TSH values outside an age-adjusted normal range and a wide range (0.1–10.0 mIU/L). Model covariates included sociodemographics, index TSH value, and a range of codiagnoses and comedications that were prevalent in the population and/or known to impact LT4 treatment. Longitudinal data were analyzed using both repeated measures (generalized estimating equations) and time-to-event (Cox proportional hazards models) methodologies. Kaplan–Meier curves were plotted to examine the incidence of out-of-range TSH values stratified by LT4 dose class. Results: The incidence of at least one out-of-range TSH value approached 25% across the entire population and exceeded 45% in the LT4 > 150 µg group. In the repeated measures analysis, a dose-dependent relationship between LT4 dose and the occurrence of TSH outside the age-adjusted range (OR: 1.98, 3.39, and 5.65 for LT4 doses of 51–100, 101–150, and >150 µg, respectively, p -values p- values <0.001). Conclusions: We identified a dose-dependent relationship between LT4 dose and suboptimal treatment over a 6-month study period. It may be beneficial for medically complex patients taking high doses of LT4 to increase TSH surveillance, in particular for those with a history of suboptimal treatment.


  • Impact of Hypothyroidism on Short-Term and Long-Term Outcomes of Coronary Artery Bypass Graft Surgery

    by Vandrize Meneghini, Fabyan Esberard de Lima Beltrão, Anis Ismail, Salim Hayek, George Golovko, Kamil Khanipov, Matthew D. Ettleson, Isabela M. Bensenor, Antonio C. Bianco

    Background: Thyroid dysfunction has been associated with adverse postoperative outcomes, but little is known about its effects on patients undergoing coronary artery bypass grafting (CABG). Here, our goals were (1) to evaluate the incidence of CABG in patients with hypothyroidism receiving thyroid hormone replacement therapy, and (2) to assess short-term and long-term outcomes in patients with hypothyroidism undergoing CABG compared with controls without thyroid disease, and (3) to determine whether abnormal preoperative thyroid-stimulating hormone (TSH) levels modify postoperative surgical risk in this patient population. Methods: Retrospective longitudinal study using the TriNetX Global Collaborative Network database. The incidence of CABG was evaluated in about 1.23 million patients with hypothyroidism during a 20-year observation period (median of 4.4 ± 5.9). Post-CABG outcomes, including mortality, cardiovascular events, and postsurgical complications, were evaluated in 6557 patients with hypothyroidism over 10 years after 1:1 propensity score-matching. Results: Over 20 years, patients with a diagnosis of hypothyroidism had a higher incidence of CABG compared with controls (0.27% vs. 0.22%; hazard ratio [HR] 1.08; confidence interval [CI]: 1.03–1.14). Among patients who underwent CABG, the diagnosis of hypothyroidism was associated with mild increased risk of short-term postsurgical infections (HR:1.10, CI:1.01–1.20), CABG-specific complications (HR: 1.24, CI: 1.08–1.42), and critical care utilization (HR:1.14, CI:1.07–1.21). During long-term follow-up, these patients were at increased risk of incident heart failure (HR:1.15, CI:1.04–1.28), stroke (HR:1.18, CI:1.01–1.39), and major adverse cardiovascular events (MACE) (HR:1.15, CI:1.01–1.29). Sensitivity analysis, including only patients with hypothyroidism diagnosis, showed that abnormal preoperative TSH levels, particularly those with elevated TSH, had a higher risk of short-term mortality and long-term embolic events. Conclusions: Hypothyroidism is associated with a higher incidence of coronary disease requiring CABG and increased risks of postoperative complications, heart failure, stroke, and MACE. These findings support the potential value of preoperative thyroid function assessment and optimization to mitigate postoperative complications and improve surgical outcomes in this high-risk group.


  • Open Access

    A Phase 2 Study of XP-8121: Once-Weekly Subcutaneous Levothyroxine Sodium for the Treatment of Hypothyroidism in Adults

    by Valentina Conoscenti, Robbie Huang, Diane Rudisill, Richard Fitch, Frances Broyles, Matthew David Ettleson, Antonio C. Bianco

    Background: The standard of care for hypothyroidism treatment worldwide is daily oral levothyroxine (LT4) sodium. Limitations associated with daily oral administration highlight the need for alternative formulations to address challenges in maintaining euthyroidism. XP-8121 (LT4 sodium for subcutaneous [SC] administration) is a ready-to-use, liquid formulation of LT4 intended for once-weekly administration, offering an alternative hormone replacement approach by bypassing the gastrointestinal tract. This study assessed the safety, tolerability, and target dose conversion factor from oral LT4 to XP-8121 SC in adult participants. Participants and Methods: This Phase 2, multicenter, nonrandomized, open-label, single-arm, self-controlled study (NCT05823012) evaluated XP-8121 SC in 46 adults with hypothyroidism receiving a consistent dose of oral LT4 for at least 3 months prior to screening, with documented normal thyrotropin (TSH) levels at least 3 months prior to screening and normal free thyroxine (fT4) at screening. The weekly XP-8121 SC dose was initiated at 50% of the target dose and titrated every 2 weeks for up to 8 weeks based on individual response using fT4 trough concentrations. Following titration, participants continued the established dose during a 4-week maintenance period. Results: Of the 46 participants enrolled, 39 completed the study. The majority were female (37; 80.4%) and identified as White (44; 95.7%). The final dose conversion factor point estimate ranged from 4.02 (90% confidence interval [CI]: 3.79–4.27) to 4.24 (90% CI: 4.06–4.42), supporting a conversion factor of approximately four times the daily oral LT4 dose when transitioning to XP-8121 SC. Although participants were initially underdosed during titration, TSH normalization was observed in 79.5% and fT4 normalization in 100% among those who completed the study on a consistent dose (unchanged for 6 weeks) at the end of maintenance. Overall, 78 treatment-emergent adverse events (TEAEs) were reported in 30 participants (65.2%) who received at least one dose of XP-8121 SC; fatigue (21.7%) and injection-site pain (10.9%) were the most common TEAEs. A majority of participants who completed the study reported higher satisfaction, convenience, and perceived effectiveness with once-weekly XP-8121 SC and expressed preference over daily oral LT4. Conclusions: Once-weekly XP-8121 SC was generally well-tolerated in all treated participants and supported a dose conversion factor of four times the daily oral LT4 dose.


  • Suboptimal Levothyroxine Treatment is Associated with Increases in Mean Blood Pressure and Blood Pressure Variability

    by Matthew D Ettleson, Nikita Thomas, Wen Wan, Donald Hedeker, Anne R Cappola, Neda Laiteerapong, Antonio C Bianco

    Context: Thyroid hormone homeostasis is critical to the metabolic function of cardiovascular tissues. The degree to which the suboptimal treatment of hypothyroidism with levothyroxine (LT4) impacts blood pressure (BP) and blood pressure variability (BPV) is not known. Objectives: Determine the relationship between LT4 time above range (TAR) (TSH level >4.5 mIU/L), time below range (TBR) (TSH <0.4 mIU/L), and changes in annual mean systolic (SBP) and diastolic blood pressure (DBP) and visit-to-visit BPV. Methods: Using longitudinal data from 2203 adult patients treated with LT4, we modeled within-individual changes in annual mean BP and BPV as a function of TAR and TBR (% time). Linear mixed-effect modeling was utilized to allow for differences in observation time between patients. Models were adjusted for sociodemographics, baseline comorbidities, weight, LT4 dose, time, and year of study enrollment. Sensitivity analyses were conducted with wide in-range boundaries (TSH 0.1-10 mIU/L) and stratification by hypertension at baseline. Results: In the primary modeling, a 100% increase in TAR was associated with significant increases in annual mean SBP and DBP (+1.8 mmHg, P = .011; +1.0 mmHg, P = .024, respectively). Similarly, a 100% increase in TBR was associated with increases in annual mean SBP and DBP (+2.7 mmHg, P = .004; +1.3 mmHg, P = .034, respectively). However, the expected differences in BP with TAR and TBR diminished in subsequent years. One hundred percent TAR and TBR were associated with small increases in annual visit-to-visit diastolic BPV (+0.67 mmHg, P = .009; +0.85 mmHg, P = .020, respectively). Conclusion: Suboptimal LT4 treatment was associated with increases in mean BP and BPV, representing potential mediators in the pathway between suboptimal LT4 treatment and cardiovascular disease.


  • Adverse Outcomes in Patients With Hypothyroidism Undergoing Bariatric Surgery: A Retrospective Study Using TriNetX

    by Vandrize Meneghini, Fabyan Esberard de Lima Beltrão, George Golovko, Riley K Watson, Sarah Samreen, Matthew D Ettleson, Isabela M Benseñor, Antonio C Bianco

    Context: Bariatric surgery (BS) effectively reduces obesity-related risks, but its outcomes in patients with preexisting hypothyroidism are unclear. Objective: To evaluate the impact of preexisting hypothyroidism on adverse health outcomes following BS. Methods: In this retrospective cohort study utilizing the TriNetX Global Collaborative Network database, patients with obesity who underwent BS or not, with and without hypothyroidism, were propensity score-matched. Short-term outcomes comprised mortality, readmission, ICU admission, and surgical and systemic complications. Long-term outcomes included mortality, major adverse events, bone health, and metabolic, renal, and neurological outcomes. Results: There were 5700 patients in each cohort (46.7 ± 12 years, 88% female). In the short term, patients with hypothyroidism exhibited higher risks of readmission (risk ratio [RR]: 1.25; CI: 1.14-1.36), incisional hernia (RR: 1.56; CI: 1.12-2.18), and biliary diseases (RR: 1.39; CI: 1.05-1.86). In the long term, patients with hypothyroidism had higher risks of incident cerebrovascular events (hazard ratio [HR]: 1.25; CI: 1.00-1.55), diabetes (HR: 1.39; CI: 1.12-1.74), and dyslipidemia (HR: 1.20; CI: 1.02-1.42). There were also higher risks of fall (HR: 1.20; CI: 1.02-1.40), osteoporosis (HR: 1.30; CI: 1.07-1.58), polyneuropathy (HR: 1.34; CI: 1.08-1.66), hypoglycemia (HR: 1.51; CI: 1.23-1.87), as well as iron (HR: 1.17; CI: 1.04-1.31) and vitamin B (HR: 1.34; CI: 1.20-1.49) deficiencies. Hypothyroidism-associated risks of poor outcomes were higher in patients who underwent gastric bypass. Compared to the nonsurgical care, patients with hypothyroidism who underwent BS showed a lower risk of obesity-related outcomes but a higher risk of iron and vitamin B deficiencies, osteoporosis, and hypoglycemia. Conclusion: Preexisting hypothyroidism in bariatric patients increases the risks of adverse outcomes. However, the risk of obesity-related outcomes is decreased in this population when compared to nonsurgical care.


  • Measuring Hypothyroidism Disease Control Using a TSH-based “Time-in-range”

    by Matthew D Ettleson, Nikita Thomas, Marcelo Ramirez, Wen Wan, Donald Hedeker, Antonio C Bianco, Neda Laiteerapong

    Context: Time-in-range (TIR) using sequential TSH levels during levothyroxine (LT4) treatment could serve as a measure of chronic disease control in hypothyroidism. Objectives: Primary objectives: (1) develop a method of estimating TIR and (2) determine the impact of patient sociodemographic characteristics on TIR. Secondary objective: investigate the relationship between TIR and time to cardiovascular event. Methods: The study was conducted using longitudinal clinical data (2016-2022) from a single academic institution. Study participants were ≥18 years old, LT4-treated, and had ≥3 unique TSH levels collected over a minimum of 2 years. For each patient, TIR, time-above-range (TAR) and time-below-range (TBR) were estimated using linear interpolation of log-transformed TSH levels. Fitted linear regression was used to evaluate the relationship between TIR/TAR/TBR and LT4 dose over the study period. Generalized estimating equations were used to model annualized TIR/TAR/TBR with sociodemographic and clinical covariates. Survival analysis was used to characterize the relationship between TIR and occurrence of cardiovascular events. Results: A total of 2752 LT4-treated patients had a median TIR of 86% over the study enrollment period (median, 3.8 years). For both males and females, LT4 dose was negatively correlated with TIR (R = −0.23 and −0.30, respectively; P < .001 for both). Male sex and Black race were associated with TIR <75% (OR, 1.30; P < .001; OR, 1.37; P < .001). The association between TAR and cardiovascular events approached significance (OR, 1.03 per +10% TAR; P = .078). Conclusion: We used TIR estimation to identify differences in disease control between sociodemographic groups and the impact of LT4 dose. In future studies, we aim to better characterize the association between TIR and clinically meaningful outcomes.


  • Treatment of Hypothyroidism That Contains Liothyronine is Associated With Reduced Risk of Dementia and Mortality

    by Fabyan Esberard de Lima Beltrão, Giulia Carvalhal, Vandrize Meneghini, Danielle Albino Rafael Matos, Daniele Carvalhal de Almeida Beltrão, Bruna Albino Rafael Matos Andrade, Fabyo Napoleão de Lima Beltrão, Helton Estrela Ramos, Miriam O Ribeiro, George Golovko, et al.

    Introduction: Standard levothyroxine (LT4) therapy may not fully address all risks associated with hypothyroidism—especially cognitive decline, dementia, and mortality—even when TSH levels are normalized. Observational studies link hypothyroidism to higher dementia rates; the role of LT4 plus T3 therapies remains uncertain. Methods: This retrospective cohort study analyzed TriNetX data, comparing 1.26 million patients with hypothyroidism (on LT4, LT4 + T3, or desiccated thyroid extract) to 3.32 million controls. Outcomes included dementia, atrial fibrillation, and mortality over 20 years of follow-up. Propensity score matching was used to balance covariates for age, sex, and comorbidities. Adjusted hazard ratios were obtained via Cox proportional hazard modeling. A parallel systematic review and meta-analysis of 12 studies evaluated dementia risk in hypothyroidism. Results: Patients with hypothyroidism showed a ∼1.4-fold higher risk of dementia and a >2.0-fold increase in mortality—even with normal TSH—and these risks were most pronounced when TSH levels were off-target. A parallel meta-analysis indicated a 1.4-fold heightened dementia risk. In cohorts formed by propensity score matching comparing LT4 monotherapy vs combination therapy, relative risk analysis indicated 27% and 31% lower dementia and mortality risks, respectively, with combination therapy. The adjusted Cox model (hazard ratio) showed 16% and 25% reductions in these outcomes for combination therapy patients. Conclusion: Despite standard LT4 therapy, hypothyroidism remains associated with heightened risks of dementia and mortality. Adding T3 may more effectively mitigate these risks than LT4 alone, but further studies are needed to confirm the cognitive and survival benefits of T3-containing regimens.


  • Open Access

    The Impact of Hypothyroidism on Cardiovascular-Related Healthcare Utilization in the US Population With Diabetes

    by Marcelo Ramirez, Antonio C Bianco, Matthew D Ettleson

    Context: Suboptimal treatment of hypothyroidism (HT) is associated with adverse cardiovascular disease (CVD) outcomes, for which patients with diabetes mellitus (DM) are at increased risk. Objective: This study aimed to compare CVD-related healthcare utilization in DM patients with and without HT in the US population. Methods: Participant data were collected from the Medical Expenditure Panel Survey (MEPS) over 10 years (2011-2020). Medical conditions were identified by ICD-9/ICD-10 codes associated with expenditures. Healthcare utilization outcomes included number of emergency, hospital, and outpatient visits associated with coronary artery disease (CAD), stroke/transient ischemic attack (TIA), or heart failure; prescriptions related to CVD; and number of visits to specialty providers. A propensity score-based fine stratification matching approach was used to balance sociodemographic covariates to determine the relative risk (RR) contributed by HT on CVD-related care utilization. Results: A total of 15 580 adult participants with DM were identified, of whom 11.9% had treated HT. In the weighted analysis, a significantly greater proportion of participants with HT had CAD and stroke/TIA-associated visits compared to those without HT (respectively, 22.4% vs 17.8%, P = .002; and 7.3% vs 5.4%, P = .020). In the matched analysis, participants with HT were more likely to see a specialist (cardiology, endocrinology, and nephrology). Participants with HT were more likely to be treated with cholesterol-lowering medications, beta-blockers, and diuretics. Conclusion: HT as a comorbidity with DM was associated with increased healthcare utilization related to CVD, specifically visits associated with stroke/TIA, increased use of specialty care, and greater utilization of CVD-related medications.


  • Treatment Preferences in Patients With Hypothyroidism

    by Giulia Carvalhal, Daniele Carvalhal de Almeida Beltrão, Fabricia Elizabeth de Lima Beltrão, Miriam O Ribeiro, Matthew D Ettleson, Helton Estrela Ramos, Antonio C Bianco

    Context: Levothyroxine (L-T4) monotherapy is the standard of care for the treatment of hypothyroidism. A minority of L-T4–treated patients remain symptomatic and report better outcomes with combination therapy that contains liothyronine (L-T3) or with desiccated thyroid extract (DTE). Objective: This work aimed to assess patient preferences in the treatment of hypothyroidism. Methods: A systematic review, meta-analysis, meta-regression, and network meta-analysis of randomized controlled trials (RCTs) comparing treatments for adults with hypothyroidism (L-T4 vs L-T4 + L-T3 or DTE). Searches were conducted in PubMed, Embase, and Cochrane databases up to April 10, 2024. Data extraction and quality assessment were independently performed by 4 researchers. Results: Eleven RCTs (8 cross-over studies) with a total of 1135 patients were considered. Overall, 24% of patients preferred L-T4 vs 52% who preferred L-T4 + L-T3 or DTE; 24% had no preference. The meta-analysis confirmed the preference for combination therapy over L-T4 monotherapy (relative risk [RR]: 2.20; 95% CI, 1.38-3.52; P = .0009). Excluding 4 studies reduced the high heterogeneity (I2 = 81%) without affecting the results (RR: 1.97; 95% CI, 1.52-2.54; P < .00001; I2 = 24%). This preference profile remained when only crossover studies were considered (RR: 2.84; 95% CI, 1.50-5.39; P < .00001). Network meta-analysis confirmed the preference for DTE and L-T3 + L-T4 vs L-T4 alone. Conclusion: Patients with hypothyroidism prefer combination therapy (L-T3 + L-T4 or DTE) over L-T4 monotherapy. The strength of these findings justifies considering patient preferences in the setting of shared decision-making in the treatment of hypothyroidism.


  • The Association Between Hypothyroidism and Cognitive Function Change in Women across the Menopause Transition: The Study of Women’s Health Across the Nation

    by Matthew D. Ettleson, Kelly Karavolos, Sherri-Ann M. Burnett-Bowie, Lynda H. Powell, Imke Janssen

    Background: Patients treated for hypothyroidism with levothyroxine (LT4) monotherapy may present with persistent hypothyroidism symptoms, including cognitive symptoms, despite having a normal thyroid stimulating hormone (TSH) level. It remains unclear whether LT4 monotherapy is sufficient to normalize cognitive function outcomes over time. Methods: This is a multisite longitudinal study of a diverse group of women during midlife representing 5 ethnic/racial groups from 7 enrollment sites across the United States in the Study of Women’s Health Across the Nation. Women were screened for a history of thyroid disease and the use of LT4. The study consisted of two primary groups: women with LT4-treated hypothyroidism and control women without thyroid disease. Each participant completed up to 9 cognitive assessments over the study period testing processing speed, working memory, and episodic memory (immediate and delayed recall). Multivariable generalized linear mixed models of scores for each cognitive assessment were developed to determine the association between LT4-treated hypothyroidism and cognitive function trajectories. Covariates included sociodemographic, clinical characteristics, and menopausal status (pre/early peri, late peri, and surgical/post). Sensitivity analyses were conducted to assess the impact of abnormal TSH levels and practice effects (i.e., improvements in scoring after repeated testing). Results: Of the 2033 women who were included in the study, 227 (11.2%) met criteria for LT4-treated hypothyroidism. At baseline, both processing speed and working memory scores were higher in LT4-treated women (mean processing speed scores: 56.5 vs 54.4; p value = 0.006; mean working memory scores: 6.8 vs 6.4; p value = 0.018). However, when considering the effect of LT4-treated hypothyroidism over time, there were no significant differences in the rate of cognitive decline (in any measure) between the hypothyroidism and control groups with or without covariate adjustment. The results were similar when considering LT4-treated women with abnormal TSH levels or after minimizing practice effects. Conclusions: We observed no difference in cognitive decline between women with LT4-treated hypothyroidism and women without thyroid disease. For similar aged patients with cognitive complaints, if thyroid function testing is normal, clinicians should consider causes other than inadequate thyroid hormone treatment to explain these symptoms.